ALMR
HOLD / NEUTRALNeutralComposite
62.00
Technical
83.30
Fundamental
47.80
Rank
—
Price
27.99
Hurst
—
As of
Aug 11, 2026
Daily
Alamar Biosciences, Inc.
HealthcareMedical DevicesAlamar Biosciences is a proteomics company that develops NULISA, a platform technology for detecting and measuring protein biomarkers in blood samples for disease diagnosis and research. The company manufactures the ARGO system, an automated instrument for high-sensitivity protein analysis, along with related supplies and analytical services used across immunology, neurology, and oncology research. The firm serves pharmaceutical companies, research institutions, and contract labs worldwide, and maintains a partnership focused on advancing Alzheimer's disease research.
Market cap
$2.2B
P/E (trailing)
—
P/E (forward)
-59.01
PEG ratio
—
Dividend yield
—
Beta
—
52w range
18.85 – 38.54
Return on equity
—
Profit margin
-49.45%
Revenue growth
+82.10%
Earnings growth
—
Price history
1Y: 32.01 (+45.5%) · range 19.09–36.57
Cycle position
48/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 33 · NOT READY · exit proximity 15
Conviction
32/ 100 · maturity 100%
VScore.408
Buildup.2065
EMA entry setup.2533
Fundamentals.1548
Volume profile
POC
24.17
Price vs POC
+32.5%
Overhead supply
14%
Runway
open sky
Value area 20.03–28.30 · 14% of 106d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.033 | Sep 8, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -20.81% | -2.82% | mature |
| 40d | -23.74% | -2.82% | 22/40d |